EpistemisEvening agitation
Specialty: Geriatrics.
Why it occurs
- Severe disruption of the circadian rhythm due to neuropathological degeneration of the suprachiasmatic nucleus
- Accumulated fatigue at the end of the day combined with the progressive decrease in ambient lighting
- Presence of undetected somatic or visceral pain due to communication failures (osteoarthritis, urinary retention, constipation)
- Stressful environmental stimuli or hyperstimulation at dusk in the care environment
- Acute subclinical infection, commonly urinary or respiratory, that alters the agitation threshold
- Adverse effect or withdrawal of sedative drugs with a short half-life administered in the morning
Initial workup
Evaluation using the Neuropsychiatric Inventory (NPI) to characterize agitation; urine dipstick and urine culture to rule out urinary tract infection; control of capillary blood glucose and serum electrolyte levels (sodium, potassium, calcium); exhaustive review of the active treatment sheet looking for drugs with a high anticholinergic load (ACB scale); elimination diary (record of bowel movements and urination); monitoring of the sleep-wake cycle and daylight exposure.
red flags
Imminent self- or heteroaggressive behavior that puts the patient or their caregivers in physical danger, terrifying visual or auditory hallucinations that induce uncontrollable panic, fluctuating confusional state with sudden spatial disorientation that increases the risk of serious falls, suspicion of acute ischemic pain (atypical angina), or acute urinary retention demonstrable by palpable bladder balloon.
Standard management
- Melatonin — 2 mg to 5 mg orally in the afternoon, administered 1 to 2 hours before sunset, to try to regularize the circadian cycle and reduce nocturnal agitation
- Risperidone — 0.25 mg to 0.5 mg orally in a single evening dose, reserved exclusively for severe conditions with risk of self-harm, monitoring extrapyramidal signs and considering the increased risk of cerebral vascular events in elderly people with dementia
- Quetiapine — 12.5 mg to 25 mg orally at night, of choice in patients with Parkinson's disease or Lewy body dementia given its low affinity for D2 receptors
- Trazodone (25 mg to 50 mg orally in the afternoon or evening, used to provide mild sedation and behavioral control without significant anticholinergic effects).
Educational guidance for study. It is NOT a prescription recommendation. The actual choice depends on the cause, the patient, and current guidelines.
- Area
- Geriatrics
- Listed causes
- 6
- Treatment options
- 4